{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:29:24Z","timestamp":1792132164836,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00848-9","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:00:03Z","timestamp":1739894403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The therapeutics effects of monobenazone on treatment of psoriasis induced in mice"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohammed Abdul Mutalib","family":"Abdul Bari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","unstructured":"Gottlieb AB, Barker JN, Boehncke W-H, et al. Psoriasis. Nat Rev Dis Primers. 2015;1:15083. https:\/\/doi.org\/10.1038\/nrdp.2015.83","DOI":"10.1038\/nrdp.2015.83"},{"key":"848_CR2","doi-asserted-by":"publisher","unstructured":"Di Cesare A, Di Meglio P, Nestle FO. The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Dermatol Treat. 2009;19(5):271\u201375. https:\/\/doi.org\/10.1038\/jid.2009.59","DOI":"10.1038\/jid.2009.59"},{"key":"848_CR3","doi-asserted-by":"publisher","unstructured":"Boehncke W-H, Sch\u00f6n MP. Keratinocytes in psoriasis: key players in the inflammatory process. Int J Mol Sci. 2019;20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475","DOI":"10.3390\/ijms20061475"},{"key":"848_CR4","doi-asserted-by":"publisher","unstructured":"Armstrong AW; Read C. Treatment of psoriasis. J Am Acad Dermatol. 2019;80(4):1029\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058","DOI":"10.1016\/j.jaad.2018.11.058"},{"issue":"Suppl 2","key":"848_CR5","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18\u2013ii23.","journal-title":"Ann Rheum Dis"},{"key":"848_CR6","unstructured":"Nordlund JJ, Boissy RE. Monobenzone: a depigmenting agent with potential applications in dermatology. J Am Acad Dermatol. 2015;73(5):791\u201398."},{"key":"848_CR7","doi-asserted-by":"publisher","unstructured":"Lee DK, Park KE, Kim BR, et al. Monobenzone-induced depigmentation: from mechanism to management. J Am Acad Dermatol. 2013;69(5):791\u201399. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.023","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"848_CR8","doi-asserted-by":"crossref","unstructured":"van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol. 2009;182(9):5836\u201345.","DOI":"10.4049\/jimmunol.0802999"},{"key":"848_CR9","doi-asserted-by":"publisher","unstructured":"van der Fits L, Mourits S, Voerman JSA, et al. Imiquimod-induced psoriasis-like skin inflammation in mice. Nat Protocols. 2012;7(12):2231\u201338. https:\/\/doi.org\/10.1038\/nprot.2012.135","DOI":"10.1038\/nprot.2012.135"},{"key":"848_CR10","doi-asserted-by":"publisher","unstructured":"Swindell WR, Johnston A, Voorhees JJ, et al. Histopathological evaluation of psoriasis-like skin lesions in a murine model. J Dermatol Treat. 2013;25(4):312\u201318. https:\/\/doi.org\/10.1016\/j.jdermsci.2013.03.003","DOI":"10.1016\/j.jdermsci.2013.03.003"},{"key":"848_CR11","doi-asserted-by":"crossref","unstructured":"Khalid-Meften A, Liaghat M, Yazdanpour M, Nabi-Afjadi M, Hosseini A, Bahreini E. The effect of monobenzone cream on oxidative stress and its relationship with serum levels of IL-1\u03b2 and IL-18 in vitiligo patients. J Cosmet Dermatol. 2024;23(12):4085\u201393.","DOI":"10.1111\/jocd.16544"},{"key":"848_CR12","doi-asserted-by":"publisher","unstructured":"Creamer D, Allen MH, Groves RW, et al. Vascular changes in psoriasis. Clin Exp Dermatol. 2010;35(1):1\u20137. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03550.x","DOI":"10.1111\/j.1365-2230.2009.03550.x"},{"issue":"1 Suppl 1","key":"848_CR13","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jaad.2005.04.035","volume":"53","author":"G Krueger","year":"2005","unstructured":"Rordam OM, Lenouvel EW, Maalo M. Successful treatment of extensive vitiligo with monobenzone. J Clin Aesthet Dermatol. 2012;5(12):36\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"848_CR14","doi-asserted-by":"crossref","unstructured":"Eberle FC, et al. Recent advances in understanding psoriasis. F1000Res. 2016.","DOI":"10.12688\/f1000research.7927.1"},{"key":"848_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","volume":"45","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, et al. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018;45:264\u201372.","journal-title":"J Dermatol"},{"issue":"6","key":"848_CR16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"848_CR17","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"M Tokuyama","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 54","key":"848_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1999.140S54001.x","volume":"140","author":"JP Ortonne","year":"1999","unstructured":"Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999;140(Suppl 54):1\u20137.","journal-title":"Br J Dermatol"},{"key":"848_CR19","doi-asserted-by":"crossref","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","volume":"355","author":"D Sugumaran","year":"2024","unstructured":"Sugumaran D, et al. Advances in psoriasis research: from pathogenesis to therapeutics. Life Sci. 2024;355:122991.","journal-title":"Life Sci"},{"key":"848_CR20","doi-asserted-by":"crossref","first-page":"1089262","DOI":"10.3389\/fimmu.2022.1089262","volume":"13","author":"Q Shen","year":"2022","unstructured":"Shen Q, et al. Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis. Front Immunol. 2022;13:1089262.","journal-title":"Front Immunol"},{"key":"848_CR21","first-page":"360","volume":"67","author":"S Chhabra","year":"2022","unstructured":"Chhabra S, et al. Recent update on immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol 2022;67:360\u201373.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"848_CR22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0733-8635(05)70415-0","volume":"15","author":"C Guzzo","year":"1997","unstructured":"Guzzo C. Recent advances in the treatment of psoriasis. Dermatol Clin. 1997;15(1):59\u201368.","journal-title":"Dermatol Clin"},{"key":"848_CR23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1755-148X.2011.00878.x","volume":"24","author":"JG van den Boorn","year":"2011","unstructured":"van den Boorn JG, et al. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigm Cell Melanoma Res 2011;24:673\u201379.","journal-title":"Pigm Cell Melanoma Res"},{"key":"848_CR24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/jid.2011.16","volume":"131","author":"JG Van Den Boorn","year":"2011","unstructured":"Van Den Boorn JG, et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol 2011;131:1240\u201351.","journal-title":"J Invest Dermatol"},{"key":"848_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/exd.12871","volume":"25","author":"CS Lee","year":"2016","unstructured":"Lee CS, et al. Different effects of five depigmentary compounds, rhododendrol, raspberry ketone, monobenzone, rucinol and AP 736 on melanogenesis and viability of human melanocytes. Exp Dermatol 2016;25:44\u201349.","journal-title":"Exp Dermatol"},{"key":"848_CR26","doi-asserted-by":"crossref","unstructured":"Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1\u03b2 and IL-6 production in mice. PLoS ONE. 2013;8(6):e67078.","DOI":"10.1371\/journal.pone.0067078"},{"key":"848_CR27","doi-asserted-by":"crossref","first-page":"e10626","DOI":"10.1371\/journal.pone.0010626","volume":"5","author":"JG van den Boorn","year":"2010","unstructured":"van den Boorn JG, et al. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One 2010;5:e10626.","journal-title":"PLoS One"},{"key":"848_CR28","doi-asserted-by":"crossref","unstructured":"Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, Becher B. Ror\u03b3t+ innate lymphocytes and \u03b3\u03b4 T cells initiate psoriasis-form plaque formation in mice. J Clin Invest. 2012;122(6):2252\u20136.","DOI":"10.1172\/JCI61862"},{"issue":"7","key":"848_CR29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1468-3083.2010.03876.x","volume":"25","author":"KM AlGhamdi","year":"2011","unstructured":"AlGhamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol. 2011;25(7):749\u201357.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"848_CR30","doi-asserted-by":"crossref","unstructured":"Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol. 2013;43(12):3138\u201346.","DOI":"10.1002\/eji.201343801"},{"key":"848_CR31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CCID.S420385","volume":"17","author":"N Tang","year":"2024","unstructured":"Tang N, et al. Erzhiwan ameliorates restraint stress-and monobenzone-induced depigmentation in mice by inhibiting macrophage migration inhibitory factor and 8-Hydroxy-2-Deoxyguanosine. Clin Cosmet Invest Dermatol. 2024;17:147\u201358.","journal-title":"Clin Cosmet Invest Dermatol"},{"issue":"1","key":"848_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/1040-0486(92)90024-C","volume":"4","author":"JJ Nordlund","year":"1992","unstructured":"Nordlund JJ, Ortonne JP. Vitiligo and depigmentation. Curr Probl Dermatol. 1992;4(1):5\u201330.","journal-title":"Curr Probl Dermatol"},{"key":"848_CR33","doi-asserted-by":"crossref","unstructured":"van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol. 2009;182(9):5836\u20135845.","DOI":"10.4049\/jimmunol.0802999"},{"key":"848_CR34","first-page":"2320","volume":"132","author":"JT Elder","year":"2009","unstructured":"Elder JT, et al. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2009;132:2320\u201331.","journal-title":"J Invest Dermatol"},{"key":"848_CR35","doi-asserted-by":"crossref","unstructured":"Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X, Nair RP, Voorhees JJ, Elder JT, Gudjonsson JE, Fisher GJ, Billi AC, Ward NL. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS ONE. 2011;6(4):e18266.","DOI":"10.1371\/journal.pone.0018266"},{"key":"848_CR36","doi-asserted-by":"crossref","unstructured":"Ueyama A, Yamamoto M, Tsujii K, Furue Y, Imura C, Shichijo M, Yasui K. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol. 2014;41(2):135\u201343.","DOI":"10.1111\/1346-8138.12367"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00848-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00848-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00848-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:55:15Z","timestamp":1742399715000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00848-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00848-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in conformity with the observation and guidelines imposed by IACUC and approved by the Ethical Review Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable, this study did not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable, this study does not contain any individual person\u2019s data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}